JacquesGalipeauMD

PubMed

• Delphi-driven consensus definition for mesenchymal stromal cells and clinical reporting guidelines for mesenchymal stromal cell-based therapeutics.
  Laurent Renesme, Kelly D Cobey, Manoj M Lalu, Tania Bubela, Raghavan Chinnadurai
  Cytotherapy. 2024-10-29
• Gα-independent and -dependent Improvements With EPA Supplementation on the Early Type 1 Diabetes Phenotype of NOD Mice.
  Rachel J Fenske, Haley N Wienkes, Darby C Peter, Michael D Schaid, Liam D Hurley
  Journal of the Endocrine Society. 2024-05-23
• Failure to launch commercially-approved mesenchymal stromal cell therapies: what's the path forward? Proceedings of the International Society for Cell & Gene Therapy (...
  Kevin P Robb, Jacques Galipeau, Yufang Shi, Michael Schuster, Ivan Martin
  Cytotherapy. 2024-05-01

Journal Articles

• GM-CSF and IL-4 fusion cytokine Induces B Cell-dependent Hematopoietic Regeneration  
  Jiusheng Deng, Andrea Pennati, Shala Yuan, Jian Hui Wu, Krishnendu Roy, Edmund Waller, Jacques Galipeau, Mol Ther, 1/1/2017
• Bone Marrow Derived Mesenchymal Stromal Cells From Sickle Cell Disease Patients Display Intact Functionality  
  Elizabeth O. Stenger, Raghavan Chinnadurai, Shala Yuan, Marco Garcia, Dalia Arafat, Greg Gibson, Lakshmanan Krishnamurti, and Jacques Galipeau, Biol Blood Marrow Transplant, 1/1/2017
• GIFT4 Fusokine Converts Leukemic B Cells into Anti-CLL Effectors  
  Jiusheng Deng, Andrea Pennati, Yuanqiang Wu, Jonathon B. Cohen, Spencer Ng, Jian Hui Wu, Christopher R. Flowers, and Jacques Galipeau, J Transl Med, 1/1/2016
• Regulatory B cells induce formation of IL-10 expressing T cells in mice with autoimmune neuroinflammation  
  Andrea Pennati, Spencer Ng, Yuanqiang Wu, Jordan R. Murphy, Jiusheng Deng, Jennifer L. Blanchfield, Brian Evavold and Jacques Galipeau, J Neurosci, 1/1/2016
• BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth  
  Deng J, Park D, Wang M, Nooka A, Deng Q, Matulis S, Kaufman J, Lonial S, Boise LH, Galipeau J, Deng X, Oncotarget, 1/1/2016
• Stimulation of natural killer cell-mediated tumor immunity by an IL-15/TGF-ß neutralizing fusion protein  
  Spencer Ng, Jiusheng Deng, Raghavan Chinnadurai, Shala Yuan, Andrea Pennati, Jacques Galipeau, Cancer Res, 1/1/2016
• Letter to the Editor - Response to "Function of Cryopreserved MSCs with and without IFN-gamma pre-licensing is Context Dependent" by Ankrum et al  
  J. Galipeau, Stem Cells, 1/1/2016
• Randomised clinical trial: safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory Crohn's disease - a phase 1 trial w...  
  Tanvi Dhere, Ian Copland, Marco Garcia, KY Chiang, Raghavan Chinnadurai, Mahadev Prasad, Jacques Galipeau and Subra Kugathasan, Aliment Pharmacol Ther, 1/1/2016
• Cryopreserved MSCs are susceptible to T-cell mediated apoptosis which is partly rescued by IFNgamma licensing  
  Raghavan Chinnadurai, Ian B Copland, Marco A Garcia, Christopher Petersen, Christopher Lewis, Edmund K. Waller, Allan Kirk, Jacques Galipeau, Stem Cells, 1/1/2016
• Challenges in animal modelling of mesenchymal stromal cell therapy for inflammatory bowel disease  
  Raghavan Chinnadurai, Spencer Ng, Vijayakumar Velu, Jacques Galipeau, World J Gastroenterol, 1/1/2015
• Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantation  
  Elizabeth O. Stenger, Lakshmanan Krishnamurti, and Jacques Galipeau, BMC Immunol, 1/1/2015
• Mesenchymal stromal cells derived from Crohn's patients deploy indoleamine 2,3-dioxygenase mediated immune suppression, independent of autophagy  
  Raghavan Chinnadurai, Ian B Copland, Spencer Ng, Marco Garcia, Mahadev Prasad, Dalia Arafat, Greg Gibson, Subra Kugathasan, Jacques Galipeau, Mol Ther, 1/1/2015
• Bone marrow Mesenchymal Stromal Cells from patients with acute and chronic GVHD deploy normal phenotype, differentiation plasticity, and immune-suppressive activity  
  Ian Copland, Muna Qayed, Marco A Garcia, Jacques Galipeau, Edmund K Waller, Biol Blood Marrow Transplant, 1/1/2015
• A GMCSF and IL7 fusion cytokine leads to functional thymic-dependent T-cell regeneration in age-associated immune deficiency  
  Hsieh J, Ng S, Bosinger S, Wu JH, Tharp GK, Garcia A, Hossain MS, Yuan S, Waller EK, Galipeau J, Clin Transl Immunology, 1/1/2015
• Blood B Cell and Regulatory Subset Content in Multiple Sclerosis Patients  
  Jakob Habib, Jiusheng Deng, Neil Lava, William Tyor, Jacques Galipeau, J Mult Scler (Foster City), 1/1/2015
• Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension: the PHACeT Trial  
  Granton J, Langleben D, Kutryk MJ, Camack N, Galipeau J, Courtman D, Stewart DJ, Circ Res, 1/1/2015
• Engineered fusokine GIFT4 licenses the ability of B cells to trigger a tumoricidal T cell response  
  Jiusheng Deng, Shala Yuan, Andrea Pennati, Jordan Murphy, Jian Hui Wu, David Lawson, Jacques Galipeau, Cancer Res, 1/1/2014
• B cells for cancer immunotherapy  
  Jiusheng Deng, Jacques Galipeau, Oncoimmunology, 1/1/2014
•  
  Chinnadurai R, Copland IB, Patel S and Galipeau J, J Immunol, 1/1/2014
• Defining the Immune Plasticity Mesenchymal Stromal Cells as a Surrogate Measure of Suppressive Potency Mini Review  
  Raghavan Chinnadurai, Jacques Galipeau, Inflammation and Regeneration, 1/1/2014
• Mesenchymal Stromal Cells as Effective Tumor Antigen-Presenting Cells in Cancer Therapeutics  
  Raphaelle Romieu-Mourez and Jacques Galipeau, Stem Cell Therapeutics for Cancer, 1/9/2013
• Matrix metalloproteinases 2 and 9 as diagnostic markers in the progression to Chagas cardiomyopathy  
  Bautista-Lopez NL, Morillo CA, Lopez-Jaramillo P, Quiroz R, Luengas C, Silva SY, Galipeau J, Lalu MM, Schulz R, Am Heart J, 1/1/2013
• MSCs: science and trials  
  Phinney DG, Galipeau J, Krampera M, Martin I, Shi Y, Sensebe L, Nat Med, 1/1/2013
• Mechanisms of Immune Modulation By Mesenchymal Stromal Cells and Clinical Translation  
  Stagg J, Galipeau J, Curr Mol Med, 1/1/2013
• Concerns arising from MSC retrieval from cryostorage and effect on immune suppressive function and pharmaceutical usage in clinical trials  
  J. Galipeau, ISBT Science Series, 1/1/2013
• Join now to see all

Books/Book Chapters

• Mesenchymal Stromal Cells: Translational Pathways to Clinical Adoption. 
  Chapter: MSC Allogeneic Vs Autologous MSCs and Donor to Donor Variability. 
  Qayed M and Galipeau JEditors: Viswanathan S, Hematti P.Academic PressEdition 1st,2017
• The Biology and Therapeutic Application of Mesenchymal Cells 
  Chapter: Mesenchymal stromal cells for the treatment of autoimmune disease. 
  Page 794 - 813Lewis C and Galipeau JEditors: Kerry Atkinson.John Wiley & Sons2016
• Adult Stem Cells 
  Chapter: Molecular and endocrine mechanisms underlying the stem cell theory of aging. 
  Coutu DL, Galipeau JEditors: Turksen K.2013
• Regenerative Therapy Using Blood-Derived Stem Cells. Book Series: Stem Cell Biology and Regenerative Medicine 
  Chapter: Mesenchymal Stem Cells and Tissue Repair. 
  Page 35 - 51Daniel L. Coutu, Moïra Francois & Jacques GalipeauEditors: David S. Allan and Dirk Strunk.2012
• Experimental and Applied Immunotherapy 
  Chapter: Mesenchymal Stromal Cells: An Emerging Cell-Based Pharmaceutical. 
  Page 127 - 148Moira Francois and Jacques GalipeauEditors: J. Medin and D. Fowler.2011
• Handbook of Experimental Pharmacology: Bone marrow-derived Progenitors. 
  Chapter: Immune plasticity of bone marrow-derived mesenchymal stromal cells. 
  John Stagg & Jacques GalipeauEditors: K. Kauser and A.M. Zeiher.Springer, Berlin, Germany2007
• Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. (as part of the NCI Cancer Drug Discovery Series) 
  Chapter: Gene Therapy for the Treatment of Cancer. Chapter 27 
  Spencer H. T & Galipeau JEditors: W. D. Figg and H. L. McLeod.Humana Press Inc., Totowa, NJ2002
• Join now to see all

Lectures

• The MSC conundrum of unmet translational expectations-analysis and potential fixes. 
  Boston, MA - 1/29/2016
• MSCs: Ability, Potency and Comparability. 
  St. Jude Children’s Research Hospital, Memphis, TN - 1/29/2016
• MSC product for clinical trials: manufacturing and potency considerations. 
  Boston, MA - 1/27/2016
• Mechanistic insights into MSC therapies. 
  Die Deutschen Universitatsklinika Regensburg, Regensburg, Germany - 1/27/2016
• MSC product for GvHD: manufacturing and potency considerations. 
  Los Angeles, CA - 1/21/2016
• Fusion cytokines: A Novel Class of Biopharmaceuticals for Enabling Cancer Cellular Immunotherapy. 
  Dartmouth-Hitchcock Norris Cotton Cancer Center, Lebanon, NH - 1/12/2016
• How mechanistic studies on Mesenchymal Stromal Cells inform design of human clinical trials for autoimmune ailments – The fitness paradigm. 
  FDA White Oak Campus, Silver Spring, MD - 1/8/2016
• Ethical Considerations for Clinical Trials. 
  1/31/2015
• Mesenchymal Stem Cell Therapies. 
  Newport Beach, CA - 1/28/2015
• The role of Academic Health Centers in developing impactful cell therapies. 
  Las Vegas, NV - 1/27/2015
• Cancer Immunotherapy. 
  1/24/2015
• Fitness of Cell Therapy Products in Human Clinical Trials - the MSC for GvHD Paradigm. 
  Istanbul, Turkey - 1/23/2015
• Mesenchymal Stromal Cells as a cellular pharmaceutical to modulate the immune response in solid organ transplantation. 
  Duke University, Durham, NC - 1/22/2015
• Fusokines: A Novel Class of Biopharmaceuticals for Enabling Cancer Cellular Immunotherapy. 
  Karmanos Comprehensive Cancer Institute, Detroit, MI - 1/22/2015
• Mesenchymal Stromal Cell Suppression of Immune Response: From Discovery to Design of Cell Therapy Studies. 
  Atlanta, GA - 1/21/2015
• Issues related to MSC cell production. 
  Lisbon, Portugal - 1/20/2015
• Innovations in Translational Medicine 351 HCT/Ps, IND requirements, Clinician and Sponsor Responsibilities. 
  1/17/2015
• Mechanistic analysis of MSCs for optimized use in clinical trials. 
  Karolinska Institutet, Stockholm, Sweden - 1/16/2015
• Mesenchymal Stromal cells in Solid Organ Transplantation. 
  Montreal, Quebec, Canada - 1/16/2015
• Fitness of MSCs in human clinical trials: From discovery to implementation of cell therapy studies for Crohn’s Disease. 
  New Orleans, LA - 1/16/2015
• The Mesenchymal Stromal Cell paradigm and how failed industrial clinical trials inform rational development of cellular pharmaceuticals. 
  Atlanta, GA - 1/12/2015
• Stem Cells, iPSCs. 
  1/28/2014
• Fitness of Cell Therapy Products in Human Clinical Trials - the MSC Paradigm. 
  Washington, DC - 1/19/2014
• Mesenchymal Stromal Cell Suppression of Immune Response: From Discovery to Implementation of Cell Therapy Studies for Crohn’s Disease. 
  Montreal, Quebec, Canada - 1/6/2014
• The Impact of Cryopreservation on Fitness of Cell Therapy Products in Human Clinical Trials - the MSC Paradigm. 
  Savannah, GA - 1/4/2014
• Join now to see all

Other

• La therapie genique: D’un enthousiasme excessif a un optimisme prudent. Invited contribution to a series on genomics 
  Galipeau, J., Massie B., Langelier Y., Piche A., Tanguay R.M., Le Devoir (a French language Montreal newspaper)
  1/29/2000